Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has signed a definitive agreement to acquire Pharmasset for $11bn.
Subscribe to our email newsletter
The transaction, when completed, is expected to be dilutive to Gilead’s earnings through 2014 and accretive in 2015 and beyond.
At present, Pharmasset’s three clinical-stage product candidates to treat hepatitis C virus (HCV) are advancing in trials.
PSI-7977, the company’s lead product candidate has entered two Phase 3 studies in genotype 2 and 3 patients.
Gilead’s research and development portfolio comprises seven unique molecules in various stages of clinical development for the treatment of HCV.
Gilead chairman and CEO John C Martin said the agreement would boost the company’s effort to treat HCV-infected patients.
"This transaction will serve to drive the long-term growth of our business, and we look forward to working closely with the Pharmasset team to advance a broad clinical program in HCV to address the unmet needs of patients and the medical community," Martin added.
The transaction is expected to close in the first quarter of 2012.